AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

PYC THERAPEUTICS LTD

2.320

+0.0703.11%

Volume:8.64M

Turnover:19.91M

Market Cap:2.28B

PE:-27.95

High:2.320

Open:2.300

Low:2.210

Close:2.250

52wk High:2.320

52wk Low:0.847

Shares:983.26M

Float Shares:348.08M

Volume Ratio:4.98

T/O Rate:2.48%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.083

EPS(LYR):-0.059

ROE:-10.14%

ROA:-6.13%

PB:3.29

PE(LYR):-39.26

Loading ...

Overview Company News Filings

PYC Therapeutics Ltd-Orphan Drug Designation Granted for Rp11 by Ema

THOMSON REUTERS

PYC Therapeutics Advances Optic Atrophy Drug to Multiple-Dose Study After Safety Clearance; Shares Up 7%

MT Newswires Live

How does Bell Potter rate these ASX healthcare stocks

PYC Therapeutics Agrees on Framework for Registrational Study Design for Blinding Eye Disease Drug Candidate New Drug Application

MT Newswires Live

How A$584 Million Equity Raise and Larger Share Base Will Impact PYC Therapeutics (ASX:PYC) Investors

Simply Wall St.

PYC Therapeutics Ltd-Joint Company Secretary Appointment

THOMSON REUTERS

PYC Therapeutics Completes Retail Entitlement Offer, Raises AU$47 Million

MT Newswires Live

PYC Therapeutics Ltd-Completion of Retail Entitlement Offer

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/PYC.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PYC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PYC.AU\",,,,,undefined,":{"symbol":"PYC.AU","market":"AU","secType":"STK","nameCN":"PYC THERAPEUTICS LTD","latestPrice":2.32,"timestamp":1788156720000,"preClose":2.25,"halted":0,"volume":8641108,"delay":0,"changeRate":0.03111111111111104,"nameEN":"PYC THERAPEUTICS LTD","floatShares":348081085,"shares":983260447,"eps":-0.083,"marketStatus":"Not Yet Opened","change":0.07,"latestTime":"08-31 16:12:00 AEST","open":2.3,"high":2.32,"low":2.21,"amount":19909118,"amplitude":0.048889,"askPrice":2.33,"askSize":50000,"bidPrice":2.2,"bidSize":303,"shortable":3,"etf":0,"ttmEps":-0.083,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1788220800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":2.25,"openAndCloseTimeList":[[1788134400000,1788156000000]],"volumeRatio":4.976423187294556,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"PYC.AU","preClose":2.25,"auctionPrice":2.32,"auctionVolume":5673943,"auction":3,"marketStatus":"盘后竞价","timestamp":1788156604294}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PYC.AU\",,,,,undefined,":{"symbol":"PYC.AU","floatShares":348081085,"roa":"-6.13%","roe":"-10.14%","lyrEps":-0.0591,"volumeRatio":4.976423187294556,"shares":983260447,"dividePrice":0,"high":2.32,"amplitude":0.048889,"preClose":2.25,"low":2.21,"week52Low":0.847,"pbRate":"3.29","psRate":"57.49","week52High":2.32,"institutionHeld":0,"latestPrice":2.32,"committee":-0.987953,"eps":-0.083,"divideRate":0,"volume":8641108,"delay":0,"ttmEps":-0.083,"open":2.3,"prevYearClose":1.655,"prevWeekClose":2.25,"prevMonthClose":2.32,"prevQuarterClose":1.685,"fiveDayClose":2.1,"twentyDayClose":1.82,"sixtyDayClose":1.235,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PYC.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-11-15","symbol":"PYC.AU","defaultRemindTime":1731625200000,"type":"split","dateTimestamp":1731589200000,"forFactor":10,"toFactor":1,"ratio":10},{"market":"AU","date":"2024-03-18","symbol":"PYC.AU","defaultRemindTime":1710716400000,"type":"split","dateTimestamp":1710680400000,"forFactor":988235,"toFactor":1000000,"ratio":0.988235}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PYC.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PYC.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2630332300","title":"PYC Therapeutics Ltd-Orphan Drug Designation Granted for Rp11 by Ema","url":"https://stock-news.laohu8.com/highlight/detail?id=2630332300","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630332300?lang=en_us&edition=fundamental","pubTime":"2026-04-27 07:49","pubTimestamp":1777247341,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260426:nTUE4GGH58:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PYC.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627748644","title":"PYC Therapeutics Advances Optic Atrophy Drug to Multiple-Dose Study After Safety Clearance; Shares Up 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627748644","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627748644?lang=en_us&edition=fundamental","pubTime":"2026-04-15 10:53","pubTimestamp":1776221591,"startTime":"0","endTime":"0","summary":"PYC Therapeutics  has been cleared by the safety review committee to advance PYC-001 candidate into a multiple ascending dose study in patients with autosomal dominant optic atrophy , following positive four-week safety and tolerability results from the 60 microgram single ascending dose trial, according to a Wednesday filing with the Australian bourse.The company is currently assessing repeat dosing in ADOA patients to evaluate safety and preliminary efficacy, aiming to establish clinical proof of concept before initiating a global registrational trial to support a new drug application, the filing said.The results from the ongoing phase one and two multiple ascending dose study will be presented throughout 2026 and 2027, the filing added.The company's shares rose 7% in recent Wednesday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","PYC.AU","BK7067","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620792448","title":"How does Bell Potter rate these ASX healthcare stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2620792448","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620792448?lang=en_us&edition=fundamental","pubTime":"2026-03-17 13:51","pubTimestamp":1773726698,"startTime":"0","endTime":"0","summary":"Bell Potter has been running the rule over a number of small-cap ASX healthcare stocks this week.Let's see what the broker is saying about these speculative stocks.Immutep is a clinical-stage biopharmaceutical company focused on developing novel LAG3 immunotherapy for cancer and autoimmune disease.Its shares were sold off this month after its lead drug, Efti, failed the futility analysis in its global Phase 3 trial in non-small cell lung cancer. Bell Potter notes that this \"is a bitterly disappointing and surprising outcome considering the strength of the company's prior Phase 1 and Phase 2 lung cancer data.\". As a result, it has downgraded its shares to a speculative hold rating with a 7 cents price target . It said:. And thanks to its recent $600 million capital raise, PYC has the benefit of >$700 million in cash, with runway into at least 2030 according to the broker. As a result, Bell Potter believes the company is \"incredibly well capitalised to execute over the next several years","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/17/how-does-bell-potter-rate-these-asx-healthcare-stocks/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/17/how-does-bell-potter-rate-these-asx-healthcare-stocks/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["PYC.AU","BK7094","IMM.AU","BK7067","CXP","BK7508","ONE.AU","BK4194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619487105","title":"PYC Therapeutics Agrees on Framework for Registrational Study Design for Blinding Eye Disease Drug Candidate New Drug Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2619487105","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619487105?lang=en_us&edition=fundamental","pubTime":"2026-03-16 09:57","pubTimestamp":1773626256,"startTime":"0","endTime":"0","summary":"PYC Therapeutics  agreed with the US Food and Drug Administration  on a framework for the design of a registrational study intended to support a new drug application for drug candidate VP-001 in retinitis pigmentosa type 11 , according to a Monday filing with the Australian bourse.The company and the US FDA agreed on the nomination of the primary endpoint, the nomination and ranking of key secondary endpoints, as well as the nomination of other secondary endpoints, the filing said.The FDA also confirmed that the company can incorporate natural history data from its study on RP11 patients with the randomized sham control arm data from the proposed registrational trial as part of the new drug application submission, per the filing.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PYC.AU","LENZ","BK7067","BK4139","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618647055","title":"How A$584 Million Equity Raise and Larger Share Base Will Impact PYC Therapeutics (ASX:PYC) Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2618647055","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618647055?lang=en_us&edition=fundamental","pubTime":"2026-03-09 11:18","pubTimestamp":1773026323,"startTime":"0","endTime":"0","summary":"PYC Therapeutics Limited recently completed a follow-on equity offering raising about A$584.14 million, issuing multiple tranches of ordinary shares at A$1.50 each, including a rights issue and subsequent direct listing on the ASX.\nThe capital raise, combined with the recent half-year results showing lower revenue and a reduced net loss, materially reshapes PYC’s funding profile and ownership structure as it progresses its therapeutic programs.\nWe’ll now examine how this large equity...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/how-a584-million-equity-raise-and-larger-share-base-will-imp","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/how-a584-million-equity-raise-and-larger-share-base-will-imp","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["EQR","PYC.AU","ISBC","BK4215","BK4585","BK4211","BK4588","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616158718","title":"PYC Therapeutics Ltd-Joint Company Secretary Appointment","url":"https://stock-news.laohu8.com/highlight/detail?id=2616158718","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616158718?lang=en_us&edition=fundamental","pubTime":"2026-03-04 16:11","pubTimestamp":1772611908,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nTUE6ZJKJ2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PYC.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616048308","title":"PYC Therapeutics Completes Retail Entitlement Offer, Raises AU$47 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2616048308","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616048308?lang=en_us&edition=fundamental","pubTime":"2026-03-04 07:59","pubTimestamp":1772582340,"startTime":"0","endTime":"0","summary":"PYC Therapeutics  completed the retail component of its pro rata accelerated non-renounceable entitlement offer of new shares, raising about AU$47 million at AU$1.50 apiece, according to a Wednesday filing with the Australian bourse.The company received applications for roughly 31 million shares, representing a take-up rate of 40%, the filing said.This comes after the institutional component of the entitlement offer and placement, which raised about AU$537 million, per the filing.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PYC.AU","BK7067","BK4539","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616377747","title":"PYC Therapeutics Ltd-Completion of Retail Entitlement Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2616377747","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616377747?lang=en_us&edition=fundamental","pubTime":"2026-03-04 06:29","pubTimestamp":1772576974,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nTUEBDPGBH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","PYC.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":28,"code":"91000000","status":"200"}]}}